Dynamic contrast-enhanced MRI for the detection of prostate cancer: Meta-analysis

American Journal of Roentgenology

Volumn 204, Issue 4, 2015, Pages W439-W448

  Tan, Cher Heng ^a   Hobbs, Brian Paul ^b   Wei, Wei ^b   Kundra, Vikas ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Dynamic contrast enhanced MRI (DCE MRI); MRI; Prostate

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; DATA ANALYSIS; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; DIAGNOSTIC USE; MALE; META ANALYSIS; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS;

CONTRAST MEDIUM;

CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84929649242     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.14.13373     Document Type: Article

References (48)

1. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MR imaging of the prostate in clinical practice. MAGMA 2008; 21:379-392
2. Sonnad SS, Langlotz CP, Schwartz JS. Accuracy of MR imaging for staging prostate cancer: a me-ta-analysis to examine the effect of technologic change. Acad Radiol 2001; 8:149-157
3. Engelbrecht MR, Huisman HJ, Laheij RJ, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229:248-254
4. Bonekamp D, Jacobs MA, El-Khouli R, Stoia-novici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions. RadioGraphics 2011; 31:677-703
5. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25:146-152
6. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010; 255:89-99
7. Fenner A. Prostate cancer: multiparametric MRI scans could be a useful adjunct for active surveillance in prostate cancer. Nat Rev Urol 2013; 10:247
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62:e1-e34
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62:1006-1012
10. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic turboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997; 203:645-652
11. Ogura K, Maekawa S, Okubo K, et al. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with his-topathologic results. Urology 2001; 57:721-726
12. Ito H, Kamoi K, Yokoyama K, Yamada K, Nishimura T. Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. Br J Radiol 2003; 76:617-624
13. Fütterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005; 237:541-549
14. Kim CK, Park BK, Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr 2006; 30:7-11
15. Bloch BN, Furman-Haran E, Helbich TH, et al. Prostate cancer: accurate determination of extracap-sular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imag-ing-initial results. Radiology 2007; 245:176-185
16. Yu JS, Chung JJ, Hong SW, Chung BH, Kim JH, Kim KW. Prostate cancer: added value of subtraction dynamic imaging in 3T magnetic resonance imaging with a phased-array body coil. Yonsei Med J 2008; 49:765-774
17. Puech P, Huglo D, Petyt G, Lemaitre L, Villers A. Imaging of organ-confned prostate cancer: functional ultrasound, MRI and PET/computed tom o graphy. Curr Opin Urol 2009; 19:168-176
18. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Sug-anuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010; 31: 625-631
19. Tamada T, Sone T, Higashi H, et al. Prostate cancer detection in patients with total serum prostate-specifc antigen levels of 4-10 ng/mL: diagnostic effcacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR 2011; 197: 664-670
20. Iwazawa J, Mitani T, Sassa S, Ohue S. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol 2011; 17:243-248
21. Chabanova E, Balslev I, Logager V, et al. Prostate cancer: 1.5 T endo-coil dynamic contrast-enhanced MRI and MR spectroscopy-correlation with prostate biopsy and prostatectomy histopath-ological data. Eur J Radiol 2011; 80:292-296
22. Novis MI, Baroni RH, Cerri LM, Mattedi RL, Buchpiguel CA. Clinically low-risk prostate cancer: evaluation with transrectal Doppler ultrasound and functional magnetic resonance imaging. Clinics (Sao Paulo) 2011; 66: 27-34
23. Bloch BN, Genega EM, Costa DN, et al. Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol 2012; 22:2201-2210
24. Fütterer JJ, Heijmink SW, Scheenen T W, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spec-troscopic imaging. Radiology 2006; 241:449-458
25. Tamada T, Sone T, Jo Y, et al. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. Radiology 2008; 248:531-539
26. Rosenkrantz AB, Mussi TC, Hindman N, et al. Impact of delay after biopsy and post-biopsy haemorrhage on prostate cancer tumour detection using multi-parametric MRI: a multi-reader study. Clin Radiol 2012; 67:e83-e90
27. Aydin H, Kizilgoz V, Tatar IG, et al. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coeffcient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. J Comput Assist Tomogr 2012; 36:30-45
28. Soylu FN, Eggener S, Oto A. Local staging of prostate cancer with MRI. Diagn Interv Radiol 2012; 18:365-373
29. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis: correlation with biopsy and histopathology. J Magn Reson Imaging 2006; 24:108-113
30. Min BD, Kim WT, Cho BS, et al. Usefulness of a combined approach of T1-weighted, T2-weighted, dynamic contrast-enhanced, and diffusion-weighted imaging in prostate cancer. Korean J Urol 2012; 53:830-835
31. Hoeks CM, Hambrock T, Yakar D, et al. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology 2013; 266:207-217
32. 11C-choline PET-CT contribute to multiparamet-ric MR I for prostate cancer localisation? Strahlen-ther Onkol 2013; 189:789-795
33. Johnson VE, Albert JH. Ordinal data modeling. New York, NY: Springer-Verlag, 1999
34. Tan CH, Wei W, Johnson V, Kundra V. Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. AJR 2012; 199:822-829
35. Padhani AR, Harvey CJ, Cosgrove DO. Angio-genesis imaging in the management of prostate cancer. Nat Clin Pract Urol 2005; 2:596-607
36. Erbersdobler A, Isbarn H, Dix K, et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 2010; 28: 687-692
37. Brawer MK. Prostate cancer detection. J Urol 1994; 151:1308-1309
38. Oto A, Yang C, Kayhan A, et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angio-genesis. AJR 2011; 197:1382-1390
39. Deray G, Rouviere O, Bacigalupo L, et al. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol 2013; 23:1250-1259
40. Choi YJ, Kim JK, Kim N, Kim KW, Choi EK, Cho KS. Functional MR imaging of prostate cancer. Ra-dioGraphics 2007; 27:63-75; discussion, 75-77
41. Verma S, Turkbey B, Muradyan N, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR 2012; 198:1277-1288
42. Tofts PS, Wicks DA, Barker GJ. The MRI measurement of NMR and physiological parameters in tissue to study disease process. Prog Clin Biol Res 1991; 363:313-325
43. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257:715-723
44. Vilanova JC, Barcelo-Vidal C, Comet J, et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specifc antigen ratio in the detection of prostate cancer. AJR 2011; 196:[web]W715-W722
45. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70:425-430
46. Casciani E, Polettini E, Carmenini E, et al. Endo-rectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prosta-tectomy. AJR 2008; 190:1187-1192
47. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59: 477-494
48. Riches SF, Payne GS, Morgan VA, et al. MRI in the detection of prostate cancer: combined apparent diffusion coeffcient, metabolite ratio, and vascular parameters. AJR 2009; 193:1583-1591